Market Size (2017)
$1.08B
Vertical: HealthcareBase Year: 2017
Market Size (2017)
$1.08B
Projected (2023)
$2.11B
CAGR (2015–2023)
11.0%
Key Players
10+
Amniotic membrane is a combination of tissues and cells which helps in wound healing by acting as foundation for re-growth of soft tissues. These are most widely used in eye surgery as a biological bandage to heal or replace damaged eye tissue. Increasing aging patient population, the rise in amniotic membrane-based transplantations globally, and rising disease awareness drive the growth of the global amniotic membrane market. However, stringent regulatory policies may hamper the growth of the market.
The global amniotic membrane market is expected to register a CAGR of 12.16% during the forecast period from 2018 to 2023. In 2017, the market was led by the Americas with 37.6% share, followed by Europe and Asia-Pacific with shares of 31.9% and 23.4%, respectively.
The global amniotic membrane market has been segmented based on the type, application, end user, and region.
Based on the type, the cryopreservation amniotic membrane segment accounted for the largest market share of 56.5% in 2017, with a market value of USD 609.44 million, which is projected to register a CAGR of 10.44% during the forecast period.
Based on application, the surgical wounds segment accounted for the largest market share of 21.8% in 2017, with a market value of USD 235.58 million, which is projected to register a CAGR of 12.47% during the forecast period.
Based on end user, the hospital & clinics segment accounted for the largest market share of 38.9% in 2017, with a market value of USD 420.25 million, which is projected to register a CAGR of 13.39% during the forecast period.
The Amniotic Membrane Market market is projected to grow at a CAGR of 11.0% from 2015 to 2023.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansAmniotic membrane is the innermost layer of the placenta, and it consists of thick basement membrane and avascular stromal matrix. Amniotic membrane is used as a dressing in different surgical procedures. In the field of ophthalmology, this is used as tissue bandage for cornea infections and to reconstruct ocular surfaces for various procedures. Moreover, increasing awareness regarding the benefit of amniotic membrane in individuals as well as healthcare professionals will create more demand for amniotic membrane products. Hence it helps to boost the growth of the global amniotic membrane market.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2017
Historical Period
2015 – 2016
Forecast Period
2018 – 2023
Primary Interviews
150+
Historical data (2015–2017) and forecast period (2017–2023)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe global amniotic membrane market seems to be a very lucrative, attractive, and profitable market, both for existing as well as new entrants. At the same time, intense rivalry among existing competitors has been observed. Our analysis revealed that market players had adopted different strategies to increase their business and position in the global amniotic membrane market. In recent years, strategic movements by major players were product launches, mergers and acquisitions, and expansions, which have been used as market penetration strategies and to reduce competition. The major players in the global amniotic membrane market are MiMedx, Osiris Therapeutics, Integra LifeSciences, Alliqua BioMedical, Inc., Skye Biologics Inc., and others.
Companies are now entering into acquisitions to neutralize growing competition from customers, competitors, and to tackle the changing market dynamics.
Company Share Analysis
There are numerous players operating in this market all over the globe. Most of these players exist in the American and European regions. There are a lot of large and small market players available in the market which provide a wide range of products for various applications. As there are many large and small players in the market, the market shares of these players are very differentiated. Some of the major players who provide amniotic membranes include MiMedx, Applied Biologics, Alliqua BioMedical, Inc., Organogenesis Inc., Integra LifeSciences, Skye Biologics Inc., Amniox Medical, Inc., Katena Products. Inc., Human Regenerative Technologies, LLC, Amnio Technology, LLC, Osiris Therapeutics, and others.
MiMedx, Osiris Therapeutics, Integra LifeSciences, and Alliqua BioMedical, are top players in the global amniotic membrane market, contributing all most 48.7% of the total global market.
Bargaining Power of Suppliers
Bargaining power of suppliers in the global amniotic membrane market is medium. The suppliers in the global amniotic membrane industry are the hospitals and specialty clinics that derive amniotic membrane from the placenta of the fetus. Currently, a moderate number of suppliers are present in the market due to stringent government regulations and high opportunities. Currently, major players are accounting for a significant share of the market. Switching cost of the suppliers is medium because suppliers tend to enter into long-term associations, partnership, and deals with the companies that sell products made using amniotic membranes.
Bargaining Power of Buyers
The bargaining power of the buyers is medium in the global amniotic membrane market due to the presence of a moderate number of providers of amniotic membrane-based products. Also, the market has a large number of buyers comprising hospitals, clinics, ambulatory surgical centers, and other specialty clinics. Also, buyers prefer products manufactured by known brands. However, there are very few big brands present in the market. Because of this, the bargaining power of the buyers is medium.
Threat of New Entrants
The threat of new entrants in the global amniotic membrane market is medium. Any company trying to enter the market is required to accept the mandatory regulatory standards issued by government authorities. The market is also characterized by a high degree of brand loyalty where establishing a brand name is difficult for newcomers. Moreover, if a company desires to survive in the market, they have to introduce innovative products for various therapeutic applications and product innovation requires a large amount of investment as well as time. Also, there are very strict government regulations which a company has to follow in the market. However, the presence of huge opportunities in the market has increased the threat of new entrants to the market.
Threat of Substitutes
The threat of substitutes in the global amniotic membrane market is low to medium. Currently, amniotic membranes do not have any direct substitutes. However, stem cell technology can be used in a few of the application areas of amniotic membranes. Hence, the threat of substitutes is low to medium in the amniotic membrane market, due to very less availability of options in the market.
Intense Rivalry
The degree of competition in the global amniotic membrane market is medium. Many companies are present in this market. These players have a moderate degree of product differentiation. They are introducing innovative and more affordable products in the market. These factors slightly increase the rivalry in the amniotic membrane market. Companies involved in amniotic membrane market are trying to acquire new players in the market and merge with major players to survive in the market. Big brands are trying to acquire small players of the market, to create a competitive edge, which is creating a medium level of rivalry in the market.
Market estimates by geography (2023)
InsightAmericas leads with $759.61M by 2023, while Asia Pacific is projected to grow fastest at a 12.0% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2015 | 2017 | 2023 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $64.97M | $93.40M | $151.97M | 11.2% | 7% |
| Americas | $348.62M | $487.90M | $759.61M | 10.2% | 36% |
| Asia Pacific | $210.45M | $312.82M | $521.02M | 12.0% | 25% |
| Europe | $290.97M | $421.16M | $681.71M | 11.2% | 32% |
| Total | $915.01M | $1.32B | $2.11B | 11.0% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$2.11B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Cryopreservation Amniotic Membrane | $1.09B | 9.4% | 52% |
| Lyophilized Amniotic Membrane | $1.02B | 13.0% | 48% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Amniotic Membrane Market covering market dynamics, competitive landscape, and strategic outlook.
The Amniotic Membrane Market market is projected to reach $2.11B by 2023, growing at 11.0% CAGR. The Cryopreservation Amniotic Membrane segment holds the largest share.
Amniotic membrane is a combination of tissues and cells which are used for biological dressing and helps in wound healing. It has anti-inflammatory, anti-bacterial, anti-immunogenic, and anti-fibrotic properties. In the early 1900s, the human placental membrane was used as a skin substitute. The amniotic membrane was first used in ophthalmology in 1940 for the treatment of ocular burn wound. Over the last 25 years, thousands of ocular surgical procedures were carried out with the help of the amniotic membrane to treat various ocular disorders. These are used in various surgical procedures as a biological dressing. These amniotic membranes are used in numerous surgical procedures such as biological bandages for burns, non-healing diabetic and venous ulcers, and repair of the abdominal hernia. The amniotic membrane is also used in eye surgeries as a biological bandage to heal damaged tissues. Over 2 million people worldwide receive treatments with amniotic membrane transplant for eye surgeries. However, factors such as the rising amniotic membrane transplantation and rapid growth in the geriatric population may hamper the growth of the market during the forecast period.
Amniotic membrane is a biological tissue that is used as a graft for corneal and conjunctival reconstruction in various ocular surface diseases. It possesses anti-scarring and anti-inflammatory properties. The amniotic membrane is also used as a biological patch, bandage, and is also used to treat acute inflammatory disorders. As per the survey carried out by the National Centre for Biotechnology Information (NCBI) in 2016, a total of 771 amniotic membrane surgeries were performed in 2016 at the University Eye Hospital Tübingen. The overall prevalence of eye disease is approximately 14% in the general population. Pterygium is a wing-shaped superficial overgrowth on the ocular surface which is characterized by inflammation and invasion of the corneal surface. Whereas, the pterygium disease is common among adults in the US. A significant increase in amniotic membrane transplantation had been observed from 2001 to 2016. As per the Center of Ophthalmology Report 2016, the mean number of amniotic membrane transplantation was 48 per year. Moreover, increasing efforts by manufacturers on R&D activities to expand the product portfolio to include injections, pre-filled syringes, and medicines to meet the rising demand for amniotic membrane are some of the factors expected to drive the revenue growth of the target market.
Developing economies pose an opportunity for various markets as they have undeveloped research and development sectors owing to which they are unable to address upcoming health challenges. Despite huge demand, the African region is dependent on imported medicines and other health technologies. Although there is a high requirement for treatment, poor economic conditions lead to the slow growth of the healthcare industry within the African region. As per the statistics of NCBI in 2016, around 180 patients from West China Hospital who underwent excision of skin lesions treated with the help of amniotic membrane lived in low- and middle-income countries. This huge population affected with the ocular disease in developing countries serves as a strong opportunity for key players operating in the amniotic membrane market.
Amniotic membrane is used for many years as an adjuvant for tissues healing. Its use has been continued to expand to other fields of orthopedics, urology, gynecology, plastic surgery, dentistry, and wound care. But these are most widely used in ocular surgery. The high cost of amniotic membrane remains one of the major barriers in the successful treatment of ocular diseases. The cost of the treatment increases exponentially with the increasing demand for an amniotic membrane for the treatment of various ocular diseases. The venous ulcers treatment costs even higher than other ocular diseases. Furthermore, healthcare reengineering paradigms that manage increasing co-morbidities such as skin disease, diabetes, and dry eye disease should offer additional potential for cost reductions in the coming years.
1.1 Pricing Analysis
Pricing is among the most important factors for any product to withstand in the market. Pricing of any product or service depends on many factors which include the cost of raw material used for the product, technology used, cost of research and development, labor charges and many other costs. Pricing plays an important role in the business to make key strategies. The amniotic membrane is a narrow range market and includes less variety of products which includes products of different prices. The cost of the product varies by technology, application, and types of product.
Amniotic membranes are used in laboratories, ambulatory surgical centers, and many hospitals to perform surgeries. The companies are focused on the use of specific technologies, to reduce the cost of the product. These products vary by its applications, and the preservation method used. So, the major companies are focusing on developing cost-effective products to grow their business in developing region such as Asia-Pacific and the Middle East.
Investment in the market highlights the growth parameters of the industry. Patents and approvals, reimbursement policies, the growth of the products based on amniotic membrane, and the complications caused due to various factors define the potential of the market. There is a huge demand or potential in the amniotic membrane market, and most of the applications are related to surgeries.
Innovation and development in the amniotic membrane market benefit both the manufacturers as well as investors, to make huge profits. Therefore, a revolution in technologies for new product offering will provide investment opportunities in the future.
Faster healing of surgical wounds using amniotic membranes
Surgical wounds generally do not heal fast. Amniotic membranes lead to a faster recovery by healing these wounds in a shorter period. So, as the number of surgeries is increasing, demand for amniotic membranes is also increasing, hence creating more investment opportunities for the global amniotic membrane market in the near future.
Rising use of amniotic membranes in ophthalmology
The increasing application of amniotic membranes in ophthalmological procedures for treatment of eye disorders like cataract and other such disorders is boosting the market growth, which in turn is creating immense opportunities for companies to invest in the market.
According to a report published by the European Pharmaceutical Review in November 2018, total US investment in medical and health R&D increased by 27% between 2013 and 2017. These investments are majorly made by the federal government and the healthcare industry, and it boosts the investment opportunities in the global amniotic membrane market.
There are various existing players manufacturing amniotic membrane-based products for the indications mentioned above, so there can be innovation done in the existing products like the product size of amniotic allografts and efficacy of amniotic membranes can be modified. Another investment opportunity is to manufacture the products, with add-on features. Companies can do business by outsourcing the manufacturing of products. So, this may reduce the cost of manufacturing.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 103 companies operating in the Amniotic Membrane Market market, including revenue, employee count, and market positioning where available.
Showing 103 of 103 companies
Company Headquarters: Georgia, US Founded: 2008 Workforce: 1000+ Company Working: MiMedx is a biopharmaceutical company which develops, manufactures, and markets regenerative biologics using human placental allografts for multiple sectors of healthcare. The company processes human placental tissue utilizing its proprietary PURION process methodology, among other processes, to produce safe and effective allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx’s portfolio includes products based on amniotic membrane, umbilical cord, placental ECM, and amniotic fluid.
Company Headquarters: California, U.S. Founded: 2006 Workforce: 200+ Company Working: Skye Biologics Inc. (Skye) develops and manufactures Biological Extracellular Matrix (BioECM) products designed to assist the body in its natural ability to remodel properly. These products are formulated to protect and augment degenerated or damaged tissues in surgical repairs and non-operative therapy as a potential alternative to surgery.
Company Headquarters: Arizona, US Founded: 2010 Company Working: Applied Biologics is a manufacturer of wound care products which are derived from amnion. It is a fully integrated life sciences company that provides research, product development, manufacturing and distribution of medical technologies. It is an outstanding worldwide source of regenerative medicine technology, clinical research, education, and training for the constantly evolving healthcare industry. Its sole focus is on products based on amniotic membranes.
Coty is a fragrance-led global beauty company and, by its own description, one of the world's largest beauty groups, with FY2026 net revenues of USD 5.81bn split roughly two-thirds Prestige (licensed and owned luxury fragrance, prestige cosmetics and skincare — Burberry, Hugo Boss, Calvin Klein, Chloé, Marc Jacobs, Davidoff, Kylie Cosmetics, Gucci until mid-2027) and one-third Consumer Beauty (mass color cosmetics such as CoverGirl, Rimmel, Max Factor and Sally Hansen; mass fragrance; and Brazilian body care). Its core competitive asset is an end-to-end fragrance platform — licensing, innovation, ~81% in-house manufacturing and global prestige distribution — that has produced blockbuster franchises such as Burberry Goddess. After five years of deleveraging under Sue Nabi, Coty entered 2026 in a reset: revenue and margins are declining, the Gucci licence exits a year early, mass color and Brazil are under strategic review, and new interim leadership is executing a "Coty.Curated" focus-and-simplify framework with leverage of 3.4x. --- **Company's own description (paraphrased from FY2026 10-K, Item 1).** Coty describes itself as one of the world's largest beauty companies with an iconic brand portfolio across fragrance, color cosmetics, and skin and body care. It states that it is focused on leveraging its leadership position and capabilities in global fragrances to fuel expansion, strengthening its presence in a limited number of structurally profitable and growing categories, and prioritising growth channels such as e-commerce and Travel Retail. Under the Coty.Curated framework it emphasises fewer, bigger initiatives, marketing sufficiency, supply reliability, consumer advocacy, more productive innovation and portfolio choices, a return to market-share growth, and AI-powered, data-driven operations. It is also evaluating its central organisation, manufacturing and asset base to resize after the Gucci exit. **What the company does.** Coty designs, manufactures (≈81% in-house, ≈19% via third-party manufacturers in FY2026), markets and distributes beauty products. The essential oils in its fragrances are generally sourced from specialist fragrance houses; Coty owns the brand development, juice selection/briefing, bottle and packaging design, filling and assembly, marketing and commercial execution. Principal raw materials are essential oils, alcohols and specialty chemicals (10-K FY2026). **Business model and revenue model.** **Value-chain position.** Coty sits between ingredient suppliers (fragrance houses, alcohol and packaging suppliers) and retailers. Its economic moat lies in (i) licence portfolio scale in prestige fragrance, (ii) innovation and launch capability (brief-to-shelf), and (iii) owned manufacturing in the U.S., Europe and Brazil. It is structurally exposed to licensors (who own the trademarks) and to concentrated retailers (Sephora, Ulta, Douglas, Walmart, drug chains, travel-retail operators). **End markets.** Prestige fragrance (core), prestige cosmetics (Kylie Cosmetics, Marc Jacobs Beauty, Gucci Beauty until FY2027), prestige skincare (Lancaster, philosophy), mass color cosmetics, mass fragrance and mists, mass skin & body care (concentrated in Brazil). **Independent characterisation.** Coty is effectively two businesses with very different economics: a high-quality, licence-dependent prestige fragrance franchise generating ~20% adjusted EBITDA margins (Prestige FY2026 adjusted EBITDA margin 20.5% per Q4 FY2026 call), and a structurally challenged mass color cosmetics/Brazil business whose segment adjusted EBITDA margin collapsed to the low single digits in FY2026 (derived). The 2025–2026 strategic actions (Wella exit, Gucci monetisation, Consumer Beauty review) are converting Coty into a narrower fragrance pure-play with lower leverage but higher licence concentration.
Codexis is a Redwood City-based enzyme engineering company in the middle of a deliberate transition. It is moving from a diversified "protein engineering" platform company, whose revenue was historically dominated by custom biocatalysts for small-molecule drug manufacturing, toward a focused provider of enzymatic manufacturing solutions for oligonucleotide therapeutics, chiefly siRNA/RNAi. Its proprietary CodeEvolver® directed-evolution platform underpins two businesses. The first is a cash-generating but lumpy pharma biocatalysis franchise, anchored by long-standing relationships with Merck & Co. and other large pharmaceutical companies, which supports about 14 commercial products. The second is the pre-commercial ECO Synthesis® Manufacturing Platform, which aims to replace solid-phase phosphoramidite chemistry with enzymatic routes, together with a commercially launched dsRNA ligase. The company is a sub-$200 million market capitalization micro-cap and remains loss-making. It has about $80 million of pro forma liquidity, a $40 million term loan, and guidance for FY2026 revenue of $72–76 million. --- ### Company's own description (FY2025 10-K / standard press-release boilerplate, paraphrased) Codexis describes itself as a leading provider of enzymatic solutions for efficient, scalable therapeutics manufacturing. It discovers, develops and improves high-performance enzymes using its proprietary CodeEvolver® technology. According to the company, its enzymes address real-world problems in small-molecule pharmaceutical manufacturing and nucleic acid synthesis. Codexis is developing the ECO Synthesis® Manufacturing Platform to enable scaled manufacture of RNAi therapeutics through an enzymatic route. It says its enzymes can raise yields, cut energy use and waste, improve manufacturing efficiency, and increase sensitivity in genomic and diagnostic applications (Codexis Q4 FY2025 and Q2 FY2026 press releases). The FY2025 10-K states that headquarters is both the administrative centre and the centre of research, development and business operations, with limited internal manufacturing capacity. In-house manufacturing produces Codex® biocatalyst panels and kits, plus enzymes for customers' pilot-scale and clinical production. The ECO Synthesis Innovation Lab sits inside headquarters and is designed to supply non-GMP material in quantities that support customers' preclinical development. The company expects to partner with CDMOs for bulk GMP-grade siRNA production for clinical supply and beyond. ### Independent characterization Codexis is best understood as a technology-licensing and specialty-enzyme supplier whose economics depend on a small number of very large pharmaceutical relationships. In FY2025 a single customer accounted for about 51% of total revenue (FY2025 10-K, "Customers"). Given the $37.8 million Merck agreement recognised mainly in Q4 FY2025, that customer is almost certainly Merck. The business model has three monetization layers. The first layer is product revenue: sales of engineered enzymes (biocatalysts), pharmaceutical intermediates, Codex® biocatalyst screening panels and kits, and, increasingly, ligase and ECO enzyme supply. Product revenue is driven by customers' commercial manufacturing schedules and is therefore volatile quarter to quarter. Product gross margin has improved structurally, from 56% in FY2024 to 64% in FY2025 and 71–73% in Q1–Q2 FY2026. Management attributes this to a shift toward higher-margin products and the run-off of lower-margin legacy products. The second layer is research and development revenue: CodeEvolver platform licence fees, technology-transfer payments, milestone payments, feasibility and evaluation fees, and ECO Synthesis manufacturing services (for example, the low-seven-figure contract to supply 50 g of siRNA). In FY2025 R&D revenue exceeded product revenue for the first time in the period analysed ($44.4 million vs. $26.0 million). The main reason was the Merck technology transfer. The third layer is royalty and contingent consideration from out-licensed or divested assets. These include the Nestlé Health Science CDX-7108 sale (up to $45 million in milestones plus a single-digit royalty), the Aldevron HiCap RNA polymerase licence (milestones and royalties), and the Roche dsDNA ligase licence (upfront and technical milestones). These are largely back-ended and uncertain. **Value-chain position.** Codexis sits upstream of drug-substance manufacturing. It supplies process technology (enzymes and the know-how to use them) to innovator pharma companies, generic manufacturers and CDMOs, which then run the commercial processes. In the oligonucleotide chain it is trying to move one step downstream. Its planned ECO GMP Manufacturing Center would make siRNA material for preclinical and Phase 1 supply. This hybrid "tool supplier plus early-phase manufacturer" model is a new risk profile for the company. **Customer types:** large innovator pharma (Merck, plus historically Pfizer, GSK and Novartis); high-growth RNAi biotech innovators (unnamed counterparties in 2025–2026 agreements); CDMOs (Bachem, Nitto Denko Avecia, Axolabs); and life-science tools companies (Roche, Aldevron, seqWell). **End-markets served:** small-molecule API manufacturing (biocatalysis); oligonucleotide/RNAi therapeutic manufacturing; and, as a residual licensing stream, life-science tools and genomics reagents. ### Revenue model mix (FY2021–FY2025) *Sources: Q4 FY2022 press release (FY2021–FY2022 PAXLOVID figures); FY2023 10-K (product revenue); Q4 FY2023 press release (ex-PAXLOVID revenue of $62.0 million implies about $8.1 million PAXLOVID-related revenue in FY2023, largely the release of deferred Pfizer fees); Q4 FY2025 8-K Exhibit 99.1 (FY2024–FY2025). Shares are computed.*
Eli Lilly is a research-based, vertically integrated pharmaceutical manufacturer that discovers, develops, manufactures and markets prescription medicines in a single reported business segment: human pharmaceutical products. Its commercial identity has been transformed since 2022 by the incretin class: tirzepatide, a dual GIP/GLP-1 receptor agonist, and from April 2026 orforglipron, an orally bioavailable non-peptide GLP-1 agonist. These assets have made Lilly the dominant player in the fastest-growing therapeutic category in pharmaceutical history, and have funded a step-change in capital deployment — more than $50 billion of announced U.S. manufacturing investment since 2020, $13.3 billion of FY2025 R&D spend, and more than a dozen acquisitions in 2026 alone. Around that core the company sustains four other franchises — oncology, immunology, neuroscience and legacy diabetes — and a direct-to-patient platform, LillyDirect. Lilly's central strategic bet is that obesity becomes a chronic-care category of unprecedented scale, and that it can own the supply, the pricing architecture and the next three generations of molecules within it. Eli Lilly and Company is, as of September 2026, the largest pharmaceutical company in the world by market capitalisation and the fastest-growing large-cap drug manufacturer by revenue. The company crossed the $1 trillion market-capitalisation threshold during 2025 — the first biopharmaceutical company ever to do so — on the strength of a single molecule, tirzepatide, commercialised under two brands (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnoea) that together generated $36.5 billion of revenue in FY2025. In April 2026 the company added the first small-molecule oral GLP-1 receptor agonist approved for obesity, Foundayo (orforglipron), to that franchise. --- ### The company's own characterisation Lilly describes itself in the FY2025 Form 10-K as a company that discovers, develops, manufactures and markets products in a single business segment — human pharmaceutical products — and states that most of the products it sells today were discovered or developed by its own scientists, with long-term success depending on the ability to continually discover or acquire, develop and commercialise innovative medicines. It manufactures and distributes through facilities in the United States (including Puerto Rico) and in Europe and Asia, and sells in approximately 105 countries. In its standard corporate boilerplate (Q2 2026 earnings release) Lilly positions itself as "a medicine company turning science into healing," with a 150-year history and scientific focus areas described as redefining diabetes care; treating obesity and curtailing its long-term complications; advancing the fight against Alzheimer's disease; addressing immune system disorders; and transforming difficult-to-treat cancers into manageable diseases. ### Independent characterisation Lilly is best understood today as three overlapping businesses operating under one P&L: **(a) The incretin platform (roughly 74% of FY2025 revenue).** Tirzepatide (Mounjaro + Zepbound) alone contributed $36.5 billion in FY2025, growing to a first-half 2026 run-rate of $27.7 billion across the two brands. Adding orforglipron (Foundayo, $98 million in its first partial quarter), legacy insulins, Trulicity and the Boehringer-partnered SGLT2/DPP-4 products, cardiometabolic health accounted for approximately $48.2 billion of FY2025 revenue. This is a volume business with unusually strong operating leverage: gross margin on the incretin portfolio has driven consolidated gross margin from 75.4% in FY2021 to 86.3% (non-GAAP) in Q2 2026, even as realised prices fell 13% year-on-year in that quarter. **(b) The diversified specialty portfolio (roughly 24% of FY2025 revenue).** Oncology ($9.4 billion), immunology ($5.2 billion) and neuroscience ($1.4 billion) constitute a conventional branded-pharma business with a normal mix of growth assets (Jaypirca, Ebglyss, Omvoh, Kisunla, Inluriyo) and mature or declining ones (Cyramza, Emgality, Taltz, Olumiant). Management has explicitly flagged this cluster as its diversification hedge: key-product revenue in immunology, oncology and neuroscience grew 121% year-on-year in Q2 2026. **(c) A capital-deployment engine.** With $16.8 billion of FY2025 operating cash flow rising to a $28.1 billion trailing-twelve-month figure at June 2026, Lilly has become one of the most acquisitive companies in the sector — at least thirteen acquisitions announced in 2026 through August — and the largest single builder of pharmaceutical manufacturing capacity in U.S. history. ### Revenue model and value-chain position Lilly's revenue is overwhelmingly product revenue. Approximately 93.5% of FY2025 revenue was product sales, with the balance (approximately $4.2 billion) collaboration and other revenue, principally from the Boehringer Ingelheim diabetes alliance, the Incyte relationship on Olumiant, royalty streams and sales-based milestones. There is no subscription revenue; "service" revenue is immaterial. The company occupies an unusually deep position in its value chain for a modern large-cap pharma: it manufactures its own active pharmaceutical ingredients, fills and finishes its own injectable devices, and, since January 2024, sells directly to patients through LillyDirect, bypassing parts of the traditional wholesaler-pharmacy-PBM chain for self-pay volumes. **Customer types and end-markets.** The direct customers are wholesalers and distributors (McKesson, Cencora, Cardinal Health in the U.S.), retail and specialty pharmacy chains, hospital systems, government purchasers (Medicare Part D plans, Medicaid programs, the Veterans Health Administration, and from 2026 the TrumpRx platform), managed-care organisations and pharmacy benefit managers, and — increasingly — patients paying cash through LillyDirect and affiliated telehealth partners. End-markets are obesity and metabolic disease, type 2 diabetes, oncology, immunology/inflammation, neurodegeneration and pain.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Mn)